The combination of anti-PD-1 with IT CXCL9/10-DC induced an overall increase in cytotoxic GzmB+CD8+ and proliferative Ki67+CD8+ T cells across all of the regions of the TME compared to monotherapies, with the most pronounced increase observed at the tumor border (0–200) (Figure 6D). Here, CD8A is linked to neoplasm.